Cost-effectiveness of cetuximab in metastatic colorectal cancer

Saturday, August 8, 2009 - 05:07 in Health & Medicine

From a health-care system perspective, it may be more efficient to use the drug cetuximab only in colorectal cancer patients whose tumors have a wild-type KRAS gene, according to a study published online August 7 in the Journal of the National Cancer Institute.

Read the whole article on Physorg

More from Physorg

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net